Notice to Readers
HIV Postexposure Prophylaxis Registry Closing
Effective December 31, 1998, enrollment of new health-care
workers
(HCWs) in the Human Immunodeficiency Virus Postexposure Prophylaxis
(HIV
PEP) Registry ceased; the goals and objectives of the registry had
been
met. In addition, continuation of the registry appeared redundant
with
other ongoing surveillance programs.
The HIV PEP Registry was established in October 1996 as a
prospective
surveillance project to monitor adverse events associated with HIV
PEP in
HCWs after occupational HIV exposures. It was a collaborative
project
managed by CDC and two pharmaceutical companies, Glaxo Wellcome
Inc. and
Merck & Co., Inc. * A designated third party, a contract research
organization, responsible for registration and follow-up, served as
the
data coordination center.
The registry data have shown that HCWs for whom HIV PEP is
prescribed
have not reported unusual adverse events (i.e., those not included
in the
prescribing information or literature) with these treatments. Data
suggest
that careful counseling about drug toxicity may be necessary to
improve
compliance with PEP among exposed HCWs. Six-week follow-up of
enrolled HCWs
will be completed.
Additional information about the registry is available from
the HIV
PEP Registry, telephone (toll-free) (888) 737-4448 until June 30,
1999, and
afterwards from CDC's Hospital Infections Program, telephone (404)
639-6425. Serious adverse events or product problems can be
reported to the
Food and Drug Administration's MedWatch program, telephone (800)
332-1088;
fax (800) 332-0178; address: HF-2, FDA, 5600 Fishers Lane,
Rockville, MD
20852-9787; or by the World-Wide Web, less than
http://www.fda.gov/medwatchgreater than .
Use of trade names and commercial sources does not imply
endorsement by
the U.S. Department of Health and Human Services or CDC.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
